<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00426101</url>
  </required_header>
  <id_info>
    <org_study_id>HLH-2004</org_study_id>
    <nct_id>NCT00426101</nct_id>
  </id_info>
  <brief_title>Treatment Protocol for Hemophagocytic Lymphohistiocytosis 2004</brief_title>
  <official_title>HLH-2004 Treatment Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Azienda Ospedaliero, Universitaria Meyer</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ehime University Graduate School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Texas Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Great Ormond Street Hospital for Children NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Anna Kinderkrebsforschung</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital de Cruces</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital JP Garrahan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Without therapy HLH is often fatal, and often rapidly fatal. The treatment protocol HLH-94
      has improved survival markedly as compared to the survival earlier. We now aim to improve
      survival further.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The most dangerous period after HLH diagnosis is the first 2 months. In HLH-2004 we provide
      additional therapy during this period as compared to in HLH-94.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>1-year after diagnosis</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Late effects</measure>
    <time_frame>5-years after diagnosis</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Hemophagocytic Lymphohistiocytosis</condition>
  <arm_group>
    <arm_group_label>Etoposide, Dexamethasone, Cyclosporin A plus IT MTX &amp; Steroids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>As compared to the HLH-94 treatment, the main changes are that
Cyclosporin A is administered from day 1 and
Intrathecal steroids are added to the intrathecal methotrexate.
Drugs, dosage, frequency and duration are described in the paragraph &quot;Interventions&quot; below.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>10 mg/m2 daily wk 1-2 5 mg/m2 daily wk 3-4 2.5 mg/m2 daily wk 5-6 1.25 mg/m2 daily wk 7 Steroids tapered wk 8
If continuation:
Pulses every 2nd wk, 10 mg/m2 for 3 days</description>
    <arm_group_label>Etoposide, Dexamethasone, Cyclosporin A plus IT MTX &amp; Steroids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>150 mg/m2 iv twice/wk (wk 1-2) 150 mg/m2 iv once/wk (wk 3-8)
If continuation:
150 mg/m2 iv, every 2nd wk</description>
    <arm_group_label>Etoposide, Dexamethasone, Cyclosporin A plus IT MTX &amp; Steroids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporin</intervention_name>
    <description>WK 1-8:
- Aim at around 200 microgram/L (trough value). Start: 6 mg/kg daily (divided in 2 daily doses) wk 1, if kidney function is normal.
If continuation:
- Aim for around 200 microgram/L. Monitor GFR.</description>
    <arm_group_label>Etoposide, Dexamethasone, Cyclosporin A plus IT MTX &amp; Steroids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intrathecal therapy</intervention_name>
    <description>If at 2 wks there are progressive neurological symptoms or if an abnormal CSF (cell count and protein) has not improved, then give 4 wkly intrathecal inj. Be aware that some pat may have increased intracranial pressure.
Methotrexate: &lt;1 yr 6 mg, 1-2 yrs 8 mg, 2-3 yrs 10 mg, &gt;3 yrs 12 mg. Prednisolone: &lt;1 yr 4 mg, 1-2 yrs 6 mg, 2-3 yrs 8 mg, &gt;3 yrs 10 mg.</description>
    <arm_group_label>Etoposide, Dexamethasone, Cyclosporin A plus IT MTX &amp; Steroids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stem cell transplant</intervention_name>
    <description>The SCT procedure is up to the treating physician. However, a suggested regimen is provided.</description>
    <arm_group_label>Etoposide, Dexamethasone, Cyclosporin A plus IT MTX &amp; Steroids</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who fulfil the diagnostic criteria of HLH.

        Exclusion Criteria:

          -  Prior cytotoxic or cyclosporin treatment for HLH.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan-Inge Henter, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Childhood Cancer Research Unit, Karolinska Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>S-171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Henter JI, Horne A, Aricó M, Egeler RM, Filipovich AH, Imashuku S, Ladisch S, McClain K, Webb D, Winiarski J, Janka G. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007 Feb;48(2):124-31.</citation>
    <PMID>16937360</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2007</study_first_submitted>
  <study_first_submitted_qc>January 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2007</study_first_posted>
  <last_update_submitted>March 12, 2017</last_update_submitted>
  <last_update_submitted_qc>March 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Jan-Inge Henter</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Hemophagocytic lymphohistiocytosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphohistiocytosis, Hemophagocytic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

